The Impact of Cytogenetic Aberrations in the Clonal Evolution of Chronic Myeloid Leukemia: A Single-Center Experience Among 450 Turkish Patients (Cohort Study)
Authors:
- Sevgi IşıkSISevgi Işık
- Gülçin GündenGGGülçin Günden
- Hava Üsküdar TekeHTHava Üsküdar Teke
- Olga Meltem AkayOAOlga Meltem Akay
- Nur Oğuz DavutoğluNDNur Oğuz Davutoğlu
- Vahap AslanVAVahap Aslan
- Mustafa KaragülleMKMustafa Karagülle
- Hülya ÖzenHÖHülya Özen
- Oğuz ÇilingirOÇOğuz Çilingir
- Sevilhan ArtanSASevilhan Artan
- Beyhan Durak ArasBABeyhan Durak Aras
Open Access
- 30 November 2022
- journal article
- research article
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 39 (4) , 237-244
Abstract
Objective: Chronic myeloid leukemia (CML) is a clonal hematologic disorder characterized by t(9;22) translocation, in which cytogenetic aberrations can occur in Ph(+) and (-) clones. These aberrations develop due to clonal evolution as well as treatment and they have prognostic significance. They are grouped as major and minor route anomalies in terms of their effects on prognostic parameters, such as treatment response, overall survival (OS), disease stage, complete cytogenetic response (CCyR), and major molecular response (MMR). It is stated that major route anomalies have unfavorable prognostic effects compared to minor route anomalies. We aimed to investigate the frequency and prognostic effects of cytogenetic anomalies detected in Ph(+) and (-) clones.Materials and Methods: In this study, we retrospectively analyzed the cytogenetic results of 450 patients diagnosed with CML between 2005 and 2020.Results: We detected cytogenetic aberrations in Ph-positive and negative clones in 41 of 450 patients. The most common anomalies were trisomy 8 (+8), additional Ph chromosome (+Ph), and loss of chromosome Y. Rarely, aneuploidy of the Y chromosome, dup (22), +11, and +6 were seen in CML patients. We observed that these identified aberrations negatively affected MMR and CCyR, and generally resulted in changing imatinib treatment for second-generation tyrosine kinase activity inhibitors. Our results are compatible with the literature.Conclusion: We suggest that cytogenetic aberrations detected in Ph(+) and (-) clones should be a warning sign in terms of treatment and require close observation. The use of cytogenetic methods for the identification of these anomalies is also important.Keywords
This publication has 22 references indexed in Scilit:
- Masked inv dup(22)(q11.23), tetrasomy 8 and trisomy 19 in a blast crisis-chronic myeloid leukemia after interrupted Imatinib-treatmentMolecular Cytogenetics, 2015
- Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CMLAnnals of Hematology, 2015
- Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitorsLeukemia, 2015
- Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysisBlood, 2012
- Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapyHaematologica, 2010
- Trisomy 6 in a CML patient receiving imatinib mesylate therapyLeukemia Research, 2008
- Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instabilityLeukemia, 2005
- Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alphaLeukemia, 2004
- Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylateLeukemia, 2003
- Trisomy 11 in a patient with Ph-negative chronic myelogenous leukemiaCancer Genetics and Cytogenetics, 1986